Abstract Great progress has been made in understanding the HCV genome and its molecular virology. This understanding has culminated in the development of direct-acting antiviral (DAA) agents targeting HCV viral proteins. Telaprevir (TVR) and boceprevir (BOC) were the first DAAs introduced for treatment of genotype 1 HCV in 2011; when used in combination with pegylated interferon (pegIFN) and ribavirin (RBV), these protease inhibitors improved efficacy in patients with chronic HCV infection compared to the traditional dual therapy. However, this combination was associated with adverse events that often led to early termination of therapy. In late 2013, the FDA approved a second wave of DAAs, sofosbuvir (SOF) and simeprevir (SMV). The use of SOF with SMVopened the door for IFN-free combination regimens. This combination was highly efficacious and well tolerated in patients with HCV genotype 1. Sofosbuvir and ledipasvir (LDV) fixed-dose oral combination (FDC) therapy, and paritaprevir/ ritonavir, ombitasvir and dasabuvir ± RBV were recently approved, elevating sustained virologic response (SVR) rates to over 95 %. We are anticipating the approval of additional IFNfree regimens with comparable efficacy and tolerability but with the addition of pangenotypic coverage, fewer drug-drug interactions, and a high barrier to resistance. This review will summarize current management for chronic HCV infection.
Introduction
HCV is a single-stranded positive RNA virus first discovered in 1989 [1] . Prior to the discovery of the viral agent, HCV was mainly transmitted via blood products [2] . Since then, injection drug use has emerged as the major mode of transmission. Other modes of transmission include vertical transmission from mother to infant and contaminated drug paraphernalia shared by noninjecting drug users (via nasal and rectal routes). While heterosexual transmission rates are rare, men who have sex with men (MSM) are at risk for HCV transmission, and the risk is compounded if they have HIV co-infection (0.07 vs. 5.6 % prevalence per year) [3, 4] . It is estimated that about 130-170 million people or 3 % of the world population is chronically infected with HCV [5] . There is an increasing burden of HCV/HIV co-infection due to overlapping modes of transmission [6] . The worldwide estimated prevalence of HCV/HIV co-infection is 5-7 million people. Of the 1.2 million HIV-infected individuals in the USA, approximately 25 % of them are co-infected with HCV [7, 8] . Chronic HCV infection is the leading cause of liver-related death and the most prominent indication for liver transplant in the USA. The estimated mortality related to HCV infection was 16,627 deaths in 2010, and this is expected to double by 2030 [9] . It takes approximately 20 to 30 years for individuals with HCV monoinfection to develop cirrhosis. This process is accelerated in patients with HIV co-infection [10] . In the era of highly active antiretroviral therapy (HAART), chronic HCV infection surpassed HIV infection as the leading cause of virus-associated mortality and morbidity. HCV treatment in this subgroup has been challenging in the era of pegylated interferon (pegIFN) and ribavirin (RBV) due to increased frequency of adverse events [11] [12] [13] . The primary goal for HCV therapy is to achieve a sustained virologic response (SVR), which is defined as undetectable HCV RNA 12 weeks after completion of therapy. HCV eradication is associated with reduction of HCV-related complications, including progression to cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), and death [14] . When making clinical decisions regarding when or who to treat, preference should be given to those patients with the greatest risk for HCVrelated morbidity and mortality. Currently available treatments can be divided into two genres, indirect-and direct-acting antiviral regimens.
HCV Life Cycle
HCV circulates as a lipoviral particle until it enters the hepatocytes via the binding of its envelope proteins to CD81, SR-B1, claudin 1, and occludin co-receptors [15] (Fig. 1 ). Once the virus is internalized into endosomal vesicles, the acidic pH environment results in fusion of viral and endosomal membranes. The viral RNA is then released into the cytoplasm, whereupon it undergoes translation, resulting in a single viral polyprotein. This polyprotein is subsequently cleaved by viral and host proteases into 10 viral proteins, three of which are structural (Core, E1, and E2) while the remainder are nonstructural (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) [16, 17] . NS3-4A protease is required for cleavage of the downstream viral peptides. It also has the ability to cleave and inactivate cellular proteins that are required for antiviral activity. Viral RNA replication takes place on an altered ER membrane, where a positivestrand RNA is copied by the NS5B RNA-dependent RNA polymerase (RdRp) into a negative-strand RNA intermediate, which in turn serves as a template for the new viral genomic RNA. This replication also requires host factors such as proteins involved in lipid metabolism, as well as micro RNA-122. The NS5B RdRp lacks proofreading capability; thus, mutations in the HCV genome develop at a rate of 10 −4 per nucleotide [18] .
The viral particles mature in the Golgi apparatus, and NS5A, a nonenzymatic protein, aids in both viral replication and assembly. Once packaged, the mature virions are released into the circulation. The direct-acting antivirals (DAAs) target the nonstructural proteins and inhibit their functions [19] .
Treatment of HCV Using Indirect-Acting Antivirals
Historically, pegIFN and RBV have been the mainstay of therapy for more than 25 years. It is important to acknowledge that these are still part of the standard of care for all genotypes for some of the developing countries. We will synopsize both the mechanism of actions and the treatment recommendations for genotypes 1-6. This is covered extensively in the American Association for the Study of Liver Diseases/Infectious Diseases Society of America (AASLD/IDSA) and European Association for the Study of the Liver (EASL) Clinical Practice Guidelines 2014 [20] .
Pegylated Interferon Alfa (pegIFN) Interferons are host proteins released in response to viral infections. These aid in the elimination of infected cells and have both antiviral activity and immunomodulatory effects [21] . There are two types of pegylated interferon alfa, 2a and 2b. PegIFN 2a is administered subcutaneously at a fixed dose of 180 μg/week, while pegIFN 2b is weight-based dosing, at 1.5 μg/kg/week.
Ribavirin (RBV)
It is a guanosine analog. Its mechanism of action is not precisely understood, but it has been proposed that it induces viral mutagenesis, inhibits viral replication, and possesses immunomodulatory effects. It is administered orally twice daily and it is weight-based dosing (<75 kg 1000 mg/ day; >75 kg 1200 mg/day). It is used in combination with pegIFN for all genotypes for variable durations. Once internalized, the viral genome is uncoated, revealing the naked viral RNA and viral nucleocapsid. The viral RNA is translated by host ribosomes into the viral polypeptide (step 3), which is then cleaved by a combination of host and viral proteases into the 10 viral proteins. Replication occurs at an endoplasmic reticulum membrane-derived replication complex (the membranous web), which includes the lipid droplet (LD) and nonstructural viral proteins NS4A-NS5B (step 4). Viral replication is also dependent on the participation of key host factors, which include miR-122 and cyclophilin A (CypA). The newly synthesized viral RNA is assembled into new LVP by the Golgi apparatus and subsequently released by the cell (steps 5 and 6). b HCV viral genome. The viral genome is a positive-sense, single-stranded RNA genome. The 5′ untranslated region (UTR) contains two important domains. The internal ribosome entry site (IRES) directs translation in a cap-independent manner. The 5′ UTR also contains two recognition sites by miR-122 that are critical for viral replication. After translation, a single viral polypeptide is generated. The structural proteins are cleaved by host proteases. The NS2/ 3 autoprotease cleaves the NS2-NS3 junction. The NS3/4A protease initially serves as an autoprotease and separates NS3-NS4A but then subsequently cleaves the remaining nonstructural proteins that patients with GT2 treated with this combination achieved the highest SVR rates of about 76-82 %. Patients with GT3 treated with pegIFN/RBV for 24-48 weeks have a much lower response rate (SVR 70 %) compared to GT2, especially in patients with cirrhosis (42-48 %) [24] . Data on the use of pegIFN/RBV for other genotypes is scant. Patients with GT4 were underrepresented in the pivotal trials, although in the subsequent studies the SVR were reported to be between 43 and 70 % and lower in the European descent [25, 26] .
Direct-Acting Antivirals (DAAs)
There are three classes of DAAs thus far which could be used in different combinations for the treatment of HCV. As of December 2014, there are three FDA-approved all-oral regimens for treatment of GT1. These included sofosbuvir and simeprevir (SOF/SMV), sofosbuvir and ledipasvir fixed-dose combination (SOF/LDV FDC), and paritaprevir/ritonavir, ombitasvir and dasabuvir with or without ribavirin. The EASL and AASLD/IDSA guidelines (2015) recommend that all treatment-naive patients with compensated chronic liver disease related to HCV who are willing to be treated and have no contraindications to therapy should be considered for treatment. They also state that treatment priority should be given to patients with advanced fibrosis or cirrhosis (Metavir score F3 to F4), clinically significant extra-hepatic manifestations such as symptomatic cryoglobulinemia or HCV immune complex nephropathy, liver transplant recipients, and patients with high risk of HCV transmission. In patients with minimal or no fibrosis, treatment may be deferred pending the development and availability of new therapies [27] . This decision should take into consideration the patient's preference and risk of progression, the presence of comorbidities, and the patient's age. In situations where treatment is deferred, it is imperative to monitor these patients regularly for disease progression. The different classes of DAAs and brief descriptions of the mechanisms of action are summarized below.
NS3/4A Protease Inhibitors (PIs)
NS3/NS4A protease inhibitors block the HCV NS3/NS4A protease enzymatic cleavage of HCV C-terminal polyprotein into discrete nonstructural proteins. Telaprevir (TVR) and boceprevir (BOC) were the first PIs to be approved by the FDA in 2011, each to be used in conjunction with pegIFN and RBV [28] . The second wave consisted of SMV licensed in November 2013 to be used in combination with pegIFN/RBV for GT1 and was just recently approved to be used in combination with SOF based on the COSMOS Study [29••] . PI regimens, especially SMV, combined with pegIFN/RBV improved SVR rates from 45 to 80 %. SVR rates were influenced by the presence of preexisting resistance mutation in the Q80K polymorphism which has a worldwide prevalence of approximately 25 % [30] . Patients who are infected with HCV GT1a and harbor the Q80K polymorphisms experience poor response to the SMV/pegIFN/RBV regimen, whereas the combination of SOF/SMV eliminates the Q80K mutation influence [31] . The SVR rates of SOF/SMV are similar between GT1a and GT1b in HIV-co-infected individuals irrespective of their Q80K mutation status [32] . The ritonavirboosted PI paritaprevir was evaluated in several phase 3 studies and was recently approved to be used in combination with ombitasvir and dasabuvir with or without ribavirin in patients with HCV GT1 infection [33•, 34•] . Other PIs expected to be licensed include grazoprevir (MK-5172) and ABT-493 [35] . Grazoprevir was evaluated in C-WORTHY phase II trial in combination with elbasvir (MK-8742, an NS5A inhibitor) with or without RBV in patients infected with HCV GT1. The study population consisted of two cohorts, treatment-naive cirrhotics (n=123) and previous null responders with or without cirrhosis (n=130). Each cohort had four arms that were randomly assigned to receive 12 or 18 weeks of grazoprevir and elbasvir with or without RBV. The SVR rates ranged from 90 % to 97 % in cohort 1 and 91 % to 100% in cohort 2 [31] . This combination was generally well tolerated. The addition of ribavirin had no added benefit and was associated with more side effects. ABT-493 is currently in phase II studies and has been evaluated in combination with ABT-530 (NS5A inhibitor). Unlike other PIs, ABT-493 has high potency against GT3a and some of the clinically important resistance-associated variants (R155 or D168 variants in GT1) that have been selected by other PIs [36] . Most of the newer PIs are once-daily regimens and appear to have less toxicity compared to the first-wave PIs [37] . They also provide a broader genotype coverage (e.g., paritaprevir has a GT1-4 and GT6 coverage) [38] .
NS5A Inhibitors
NS5A is a nonstructural protein that is critical for both viral replication and assembly. It exists in phosphorylated and hyperphosphorylated forms which are implicated in different life cycle functions. The precise mechanism of action for NS5A inhibitors is unknown, however, it has been suggested that they inhibit the hyperphosphorylation process required for viral production and they alter the subcellular localization of NS5A resulting in faulty viral assembly [39] . NS5A has three cytoplasmic domains: domain 1 lacks the amphipathic helix and spanning residues and has a potential role in RNA binding; the functions of the other two domains remain unknown. It is believed that there is a direct interaction between NS5A and NS5B RdRp such that the in vitro interaction catalyzes RdRp-dependent synthesis of negative RNA strands. A combination of DCV plus SOF has demonstrated high SVR rates in both previous null responders (100 % in the 24-week arm without RBV) and treatmentnaive noncirrhotic (100 % in the 12 week arm without RBV) GT1 HCV-infected individuals [46] . GS-5816, a pangenotypic NS5A inhibitor with picomolar potency against GT1-6, has been evaluated in combination with SOF for treatment of all the HCV genotypes with remarkable SVRs among GT1 and GT3 patients. In the ELECTRON-2 Study, the GT3 HCV-infected treatment-naive group without cirrhosis demonstrated SVR rates of 100 % when GS-5816 (100 mg) was used in combination with SOF for 12 weeks, and this was irrespective of RBV use. Among the treatmentexperienced GT3 patients, the SVR rates were 96 % and only one patient experienced virologic relapse [47] .
NS5B Polymerase Inhibitors
There are two main classes of NS5B polymerase inhibitors, namely nucleos(t)ide inhibitors and nonnucleos(t)ide inhibitors. The nucleos(t)ide inhibitors bind to the polymerase's active site, while the nonnucleosides bind to allosteric sites of the enzymes, causing conformational changes that in turn inhibit the polymerase activity. Sofosbuvir is a nucleotide polymerase inhibitor. It is well tolerated without overt mitochondrial toxicity. It also has a pangenotypic coverage given the remarkable conservation of the active site across genotypes and a high barrier to resistance as mutations in the active site of the NS5B polymerase result in profound abrogation of viral fitness. Excellent SVR rates have been observed in most studies using SOF, and in vivo resistance mutations are rare and without significant clinical consequences [48] . Dasabuvir is a nonnucleoside NS5B polymerase inhibitor that is used in combination with paritaprevir/r, ombitasvir with or without RBV. It has been evaluated in PEARL Treatment-naive patients infected with GT3 should be treated with SOF (400 mg) and weight-based RBV for 24 weeks. The SVR rates associated with this combination have been reported to be as high as 95 % in treatment-naive individuals without cirrhosis and 92 % in those with cirrhosis (VALENCE study) [48] . The SVR rates were lower in the treatment-experienced group especially those with advanced fibrosis and or cirrhosis (87 % vs. 62 %). The alternative treatment option for IFN-eligible individuals would be SOF, weight-based RBV, and pegIFN for 12 weeks. This yielded similar SVR rates (92 %) to the SOF/RBV combination in treatment-naive patients with early fibrosis. Patients with advanced fibrosis/cirrhosis had a lower SVR rate (83 %) with this combination. A few studies (VALENCE and FISSION) have suggested that a longer duration of therapy with SOF/RBV for patients with cirrhosis may yield better results. The combination of SOF and DCV has been evaluated among patients infected with HCV GT3. This study included 18 treatment-naive noncirrhotic HCV GT3 patients treated for 12 weeks; the SVR rate was 89 %. Of the two patients that failed to achieve SVR, one demonstrated a preexisting NS5A-A30K polymorphism which is associated with DCV resistance [45••] . DCV is expected to be approved by the end of 2014. SOF/LDV FDC in combination with RBV has recently been shown to produce the highest SVR (100 %) among treatment-naive HCV GT3 patients [57] .
Genotype 4
The current recommended treatment for patients with GT 4 includes SOF (400mg)/LDV (90mg) FDC for 12 weeks, paritaprevir (150mg)/ritonavir (100mg)/ombitasvir (25mg) and weight-based RBV for 12 weeks, or sofosbuvir (400 mg) and weight-based RBV plus PEG-IFN for 12 weeks. The SYNERGY trial evaluated the efficacy of the approved SOF/ LDV FDC for 12 weeks in 21 patients infected with GT4. Majority of the patients were black, 10 % had advanced fibrosis, and 33 % had compensated cirrhosis. The SVR rate was 95 % and this combination was well tolerated, even in patients with cirrhosis [58] . The combination of paritaprevir/ritonavir, ombitasvir, with or without ribavirin was evaluated in the PEARL-1 trial which consisted of three arms of both treatment-naive and treatment-experienced individuals [59] . The treatment-experienced arm was assigned to receive paritaprevir/ritonavir, ombitasvir, and ribavirin for 12 weeks, and the treatment-naive groups were assigned to paritaprevir/ ritonavir and ombitasvir with or without RBV. The SVR rate was 100 % in both the treatment-experienced and treatmentnaive ribavirin-containing arms. In the treatment-naive ribavirinfree group, the SVR rate was 91 %; one patient experienced virologic breakthrough and two patients had virologic relapse. None of the patients in this cohort had cirrhosis. The commonest adverse events were fatigue, headache, and insomnia and four patients had RBV dose reduction for anemia [59] . The NEU-TRINO trial, which included 28 patients infected with GT4 treated with SOF/PegIFN/RBV for 12 weeks, showed an SVR rate of 96 % [60] . Alternatively, for patients who are ineligible for pegIFN-based therapy, one could consider the combination of SOF and weight-based RBV for 24 weeks. The SVR rates are 100 % in treatment-naive and 93 % in treatment-experienced individuals [61] .
Genotypes 5 and 6
There is limited data to guide treatment in patients with these two genotypes. For those patients who cannot afford to wait to be treated, SOF (400 mg), weight-based RBV, and pegIFN for 12 weeks is the most optimal therapy based on the NEUTRINO trial [60] . The alternative therapy remains pegIFN/RBV for 48 weeks. We are looking forward to clinical trials that will include countries where genotypes 5 and 6 are prevalent to pave the way for IFN-free regimens in these patients. A two-center open-label study that evaluated the efficacy of SOF/LDV FDC for 12 weeks in 25 patients infected with HCV GT6 has demonstrated promising results. The SVR rate reported was 96 % (24/25), and the one patient who relapsed had discontinued therapy at 8 weeks due to intravenous drug use. Majority of these patients (92 %) were treatment naive and only 8 % had cirrhosis [62] . The treatment summary for all genotypes can be found in Table 1 .
Treatment Options for Specific Groups

Cirrhosis
All patients with compensated cirrhosis should be treated. PegIFN/RBV should be avoided given the risk of hepatic decompensation. Most oral DAAs are well tolerated with the exception of SMV. Simeprevir is primarily metabolized by the liver, and patients with moderate to severe hepatic impairment (Child-Pugh class B and C) could experience accumulation of drug levels; thus, SMV should be avoided beyond Child-Pugh class A. Treatment-naive patients with compensated cirrhosis including those with HCC should receive the same treatment as recommended for patients without cirrhosis. SOF/LDV FDC has been shown to be well tolerated and efficacious in patients with cirrhosis. The reported SVR rates were 94% in treatment-naive patients treated for 12 weeks, 86% and 100% in treatmentexperienced patients treated for 12 and 24 weeks, respectively
. Patients with decompensated cirrhosis should be referred for liver transplant, and if liver transplant is not an option, SOF/RBV for 48 weeks is the recommended therapy (AASLD/ IDSA/IAS-USA) for all genotypes. The benefit of treating these patients is a significant reduction in incidence for decompensation and the lower rates of HCV recurrence post-transplant. These patients require close monitoring due to increased frequency of hematological side effects.
HCV/HIV Co-infection
Patients with HCV/HIV co-infection are at risk for accelerated liver disease progression, and thus, it is imperative to treat the HCV infection. Successful HCV eradication in this subgroup is associated with a reduction in all cause and liver-related mortality [65] . The previous standard therapy of pegIFN and RBV was associated with disappointingly low SVR rates (<30 %) for GT1 [66] . The first-generation PIs (TVR-and BOC-based regimens) improved the treatment efficacy such that the SVR rates were on par with the HIV-negative patients. However, treatment toxicities and drug-drug interactions posed challenges for their use in the co-infected population. Sofosbuvir metabolism is independent of cytochrome P450; thus, it has less drug-drug interaction with the contemporary HAART regimens. The PHOTON-1 and PHOTON-2 studies evaluated the use of SOF with RBV in both treatment-naive and treatment-experienced HCV/HIV-co-infected individuals. This combination produced SVR rates exceeding 80 % across GT1 to GT3, including patients with advanced fibrosis [67] . The recently approved SOF/LDV FDC, with remarkably high SVR rates among the HCV-monoinfected individuals, is currently being evaluated in the phase III ION-4 study of HCV/HIV-co-infected population. A recent phase II study of 50 HCV/HIV-co-infected patients on a wide range of ART regimens evaluating the use of SOF/LDV FDC has revealed 100 % SVR8 and SVR12 rates [68••] . High rates of response may also be accomplished with other DAA combinations. A SOF sofosbuvir (400 mg/daily), SMV simeprevir (150 mg/daily), pegIFN pegylated interferon (180 μg/weekly sc), RBV ribavirin (weight based 1000 mg <75 kg and 1200 mg >75 kg), LDV ledipasvir (90 mg) study assessing the use of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir, and RBV in 63 HCV/HIV-co-infected patients showed a promising SVR rate [69••] . These subjects were on raltegravir-or boosted atazanavir-based ART regimens. There was no drug-drug interaction observed except for a rise in total bilirubin in patients receiving atazanavir. Overall, all-oral pegIFN-free regimens with comparable SVR, good tolerability, and safety profile appear to be achievable in HCV/HIV-coinfected patients.
Renal Failure and Patients on Hemodialysis
The recommendation prior to availability of all-oral DAAs has been to treat patients with renal failure or patients on hemodialysis with pegIFN/RBV prior to planned renal transplant because of deleterious effects of pegIFN on graft survival [70] . Treatment in this population is challenging as one needs to modify the medication dosages according to the creatinine clearance (CrCl), leading to suboptimal therapy [71, 72] . The major elimination pathway for SOF is via renal excretion; however, studies have shown that no dosage modification is required in patients with mild (GFR 60-89 ml/min/1.73 m ) or those that require hemodialysis due to the concern of retained SOF metabolites. Studies of SOF dosing in severe renal impairment are ongoing. The safety and efficacy of SMV and LDV has not been studied in patients with severe renal impairment including patients on dialysis. SMV is highly protein bound and dialysis is unlikely to result in significant removal of its metabolites. It has good oral bioavailability and does not require dose adjustment in mild to moderate kidney disease.
Post-liver Transplant HCV Recurrence HCV remains the leading indication for liver transplant in the USA. The outcomes are poor for patients with active viremia undergoing transplant. Approximately 20-30 % of these patients will develop cirrhosis within 5 years if not treated. In the era of pegIFN and RBV, it was advisable to treat these patients prior to liver transplantation to avoid the risk of interferoninduced plasma cell hepatitis in the allograft. The new FDAapproved DAAs (SOF/LDV and SOF/RBV) are well tolerated post-transplant. With the exception of PIs, which are metabolized in the liver via the cytochrome p450 enzyme, SOF and LDV require no dose adjustment when used with calcineurin inhibitors (CNI) [73] . In a prospective multicenter study of 40 treatment-naive and treatment-experienced liver transplant patients infected with GT1, 3, and 4, where a combination of SOF and RBV was administered for 24 weeks, 70 % of patients achieved SVR. In this study, 40 % of the patients had cirrhosis and 83 % were treatment experienced. Overall, this combination was well tolerated with no CNI toxicities or drug interactions [74] . Other recommended treatment options for treating patients with HCV GT1 recurrence post-transplant include SOF/SMV with or without RBV for 12-24 weeks or SOF/LDV FDC with RBV for 12 weeks. In a recent prospective study, SOF/LDV FDC with RBV was evaluated in 223 post-liver transplant patients infected with G1 and GT4. The median post-transplant period was 4.4 years. This study consisted of both treatment-naive (17 %) and treatmentexperienced (83 %) individuals. Approximately 50 % of patients had mild to moderate fibrosis (Metavir F0-F3) . The study included patients with both compensated and decompensated cirrhosis (Child-Pugh class A to C). The SVR4 in the noncirrhotic patients were 96 and 94 % in the 12-and 24-week arms, respectively. The SVR4 in patients with cirrhosis were 92 and 82 % in the 12-and 24-week arms, respectively. Overall, this combination was well tolerated; five deaths were reported in the cirrhotic cohort. The fatalities were not drug related; few were due to complications of cirrhosis, one aortic dissection; and others had progressive multifocal leukoencephalitis [75] . Another treatment option for HCV GT1 recurrence includes a combination of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir, and ribavirin. This combination was evaluated in the CORAL-1 study that consisted of 34 liver transplant patients with minimal or no fibrosis. The majority of patients tolerated therapy (33/34 patients) for 24 weeks with a low rate of adverse events. Only one patient discontinued therapy at 18 weeks due to severe rash, memory impairment, and anxiety all thought to be drug related. The SVR12 in this cohort was 97 %. Ribavirin-associated anemia was the most common adverse event, with 9 patients requiring ribavirin dosage adjustment and 5 patients requiring erythropoietin administration. There was no blood transfusion required [76] .
Conclusion
Chronic HCV infection has been a major burden in most health-care systems for decades. The past 3 years has been witness to major breakthroughs in new drug development against HCV. The once difficult to treat GT1, which predominates in the USA and worldwide, can now be cured in 12 weeks or less with all-oral interferon-free direct-acting antivirals. These new regimens are effective not only in the treatment-naive population but also in the difficult to treat populations, such as cirrhotics, patients with HBV and HIV co-infection, and liver transplant recipients. Challenges remain ahead for the prevention, identification, and early diagnosis of chronic HCV infection, as well as the delivery of medications to those who need to be treated. The residual damage incurred over the past few decades may still linger and lead to complications even as we successfully treat most chronic infections.
